Depression Clinical Trials in Georgia

47 recruiting studies across 1 city

Browse by City

All Trials in Georgia

Phase

Trial	Phase	Sponsor	Dist.
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.	Phase 3	AbbVie	<1 mi
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD	Phase 3	Lipocine Inc.	<1 mi
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)	Phase 3	Cybin IRL Limited	<1 mi
The RAFT ECT Study	N/A	The George Institute	<1 mi
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder	N/A	Emory University	<1 mi
Leucine in Midlife Depression	Phase 2	Emory University	<1 mi
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder	Phase 2	AbbVie	<1 mi
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder	Phase 3	Neumora Therapeutics, Inc.	<1 mi
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine	Early 1	Emory University	<1 mi
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"	Phase 3	Cybin IRL Limited	<1 mi
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)	N/A	Abbott Medical Devices	<1 mi
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms	Phase 4	Axsome Therapeutics, Inc.	<1 mi
Mechanisms of Behavioral Activation (BA)	N/A	Emory University	<1 mi
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	<1 mi
Dopaminergic Therapy for Anhedonia - 2	Phase 4	Emory University	<1 mi
Brain Stimulation and Decision-making	N/A	Emory University	<1 mi
JAK Signaling in Depression	Phase 2	Emory University	<1 mi
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression	Phase 2	Draig Therapeutics Ltd	<1 mi
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder	Phase 3	Neumora Therapeutics, Inc.	<1 mi
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder	Phase 3	Cybin IRL Limited	<1 mi
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)	Phase 2	Autobahn Therapeutics, Inc.	<1 mi
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms	Phase 3	Janssen Research & Development, LLC	<1 mi
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study	Phase 3	Yale University	<1 mi
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder	Phase 2	AbbVie	<1 mi
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)	Phase 3	Xenon Pharmaceuticals Inc.	<1 mi
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder	Phase 3	Janssen Research & Development, LLC	<1 mi
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder	Phase 2	Sirtsei Pharmaceuticals, Inc.	<1 mi
Inflammation and Depression in People With HIV	Phase 2	Emory University	<1 mi
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder	Phase 2	Janssen Research & Development, LLC	<1 mi
Study to Assess the Safety and Effectiveness of NMRA-335140-501	Phase 3	Neumora Therapeutics, Inc.	<1 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)	Phase 3	Xenon Pharmaceuticals Inc.	<1 mi
The OBSERVE Protocol	—	Yale University	<1 mi
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	<1 mi
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A	LivaNova	<1 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder	Phase 3	Xenon Pharmaceuticals Inc.	<1 mi
ALTO-100 in Bipolar Disorder With Depression (BD-D)	Phase 2	Alto Neuroscience	<1 mi
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)	Phase 2	Seaport Therapeutics	<1 mi
E-Mindfulness Approaches for Living After Breast Cancer	Phase 3	NRG Oncology	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.	Phase 2	LB Pharmaceuticals Inc.	6 mi
A Study of Brenipatide in Adult Participants With Major Depressive Disorder	Phase 3	Eli Lilly and Company	6 mi
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)	Phase 2	atai Therapeutics, Inc.	6 mi
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	13 mi
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor	Phase 4	Neurocrine Biosciences	17 mi
Study of ALTO-300 in MDD	Phase 2	Alto Neuroscience	22 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.